Uno studio per valutare la sicurezza e l'efficacia di Bomedemstat (MK-3543-017)
Uno studio di estensione multicentrico, in aperto, che valuta la sicurezza e l'efficacia di Bomedemstat per il trattamento dei partecipanti arruolati in un precedente studio clinico su Bomedemstat
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria:
- Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat;
- Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic response.
No hypothesis testing will be conducted in this study.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Toll Free Number
- Numero di telefono: 1-888-577-8839
- Email: Trialsites@msd.com
Luoghi di studio
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Reclutamento
- Royal Prince Alfred Hospital ( Site 1003)
-
Contatto:
- Study Coordinator
- Numero di telefono: +61295155720
-
St Leonards, New South Wales, Australia, 2065
- Reclutamento
- Royal North Shore Hospital ( Site 1001)
-
Contatto:
- Study Coordinator
- Numero di telefono: +61299264383
-
-
Queensland
-
Buderim, Queensland, Australia, 4556
- Reclutamento
- Sunshine Coast Hematology and Oncology Clinic ( Site 1006)
-
Contatto:
- Study Coordinator
- Numero di telefono: +61754790000
-
Southport, Queensland, Australia, 4215
- Reclutamento
- Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002)
-
Contatto:
- Study Coordinator
- Numero di telefono: +61756872712
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Reclutamento
- Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000)
-
Contatto:
- Study Coordinator
- Numero di telefono: +61870740000
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Reclutamento
- Monash Health ( Site 1004)
-
Contatto:
- Study Coordinator
- Numero di telefono: +61395956111
-
-
-
-
-
Hksar, Hong Kong
- Attivo, non reclutante
- Queen Mary Hospital ( Site 1601)
-
-
-
-
-
Alessandria, Italia, 15121
- Reclutamento
- Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703)
-
Contatto:
- Study Coordinator
- Numero di telefono: +39 0131 206440
-
Bologna, Italia, 40138
- Reclutamento
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702)
-
Contatto:
- Study Coordinator
- Numero di telefono: +390512143044
-
Varese, Italia, 21100
- Reclutamento
- Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701)
-
Contatto:
- Study Coordinator
- Numero di telefono: +390332393906
-
-
Tuscany
-
Florence, Tuscany, Italia, 50134
- Reclutamento
- Azienda Ospedaliera Universitaria Careggi ( Site 2700)
-
Contatto:
- Study Coordinator
- Numero di telefono: +39 0131 206440
-
-
-
-
-
Auckland, Nuova Zelanda, 0622
- Attivo, non reclutante
- North Shore Hospital-Department of Haematology ( Site 1401)
-
Auckland, Nuova Zelanda, 2025
- Attivo, non reclutante
- Aotearoa Clinical Trials ( Site 1400)
-
-
-
-
Hammersmith and Fulham
-
London, Hammersmith and Fulham, Regno Unito, W12 0HS
- Reclutamento
- Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402)
-
Contatto:
- Study Coordinator
- Numero di telefono: +442083834340
-
-
Lincolnshire
-
Boston, Lincolnshire, Regno Unito, PE21 9QS
- Reclutamento
- Boston Pilgrim Hospital ( Site 3403)
-
Contatto:
- Study Coordinator
- Numero di telefono: 01205 446311
-
-
London, City of
-
London, London, City of, Regno Unito, NW1 2PG
- Reclutamento
- University College London Hospital ( Site 3400)
-
Contatto:
- Study Coordinator
- Numero di telefono: +442034472528
-
London, London, City of, Regno Unito, SE1 9RT
- Reclutamento
- Guy's & St Thomas' NHS Foundation Trust ( Site 3401)
-
Contatto:
- Study Coordinator
- Numero di telefono: +442071884259
-
-
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- University of Michigan ( Site 6000)
-
Contatto:
- Study Coordinator
- Numero di telefono: 734-763-4695
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27705
- Reclutamento
- DUHS Duke Blood Cancer Center ( Site 6005)
-
Contatto:
- Study Coordinator
- Numero di telefono: 919-668-1608
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)
-
Contatto:
- Study Coordinator
- Numero di telefono: 888-577-8839
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- Reclutamento
- UPMC Hillman Cancer Center ( Site 6004)
-
Contatto:
- Study Coordinator
- Numero di telefono: 412-864-6627
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Is from a bomedemstat study sponsored by Imago BioSciences, Inc. (a subsidiary of Merck & Co., Inc.) or MSD, and established by the Sponsor as MK-3543-017 ready
- Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202/MK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator
- ET and PV participants from established feeder studies other than IMG-7289- 202/MK-3543-005 must have achieved confirmed hematologic response, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator
- Is not currently on a dose hold
- Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat
Exclusion Criteria:
- Has received prohibited concomitant medications
- Ongoing or planned participation in another investigational study
- Has noncompliance in prior bomedemstat study receiving <90% of assigned doses excluding suspensions or holds as assigned by the investigator
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Bomedemstat
Participants will receive oral capsules of bomedemstat once daily for up to 10 years, with the starting dose as the same dose that the participant was on at the time of transition from the feeder study. |
10, 15, 20, and 50 mg oral capsules
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of participants with one or more adverse events (AEs)
Lasso di tempo: Up to ~10 years
|
An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants with AEs will be presented. |
Up to ~10 years
|
|
Percentage of participants who discontinued study treatment due to an AE
Lasso di tempo: Up to ~10 years
|
An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants who discontinued study treatment due to an AE will be presented. |
Up to ~10 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
For participants with ET: Duration of durable clinicohematologic response
Lasso di tempo: Up to ~10 years
|
For participants who demonstrate durable clinicohematologic response (DCHR) in their feeder study, duration of durable clinicohematologic response (DODCHR) is defined as the time from the first documented evidence of confirmed reduction of platelet and white blood cell (WBC) counts until confirmed increase of platelet and WBC counts to above acceptable threshold, thrombotic or major hemorrhagic events, or disease progression to myelofibrosis (MF), myelodysplastic syndrome (MDS), or acute myeloid leukemia (AML). DODCHR will be reported. |
Up to ~10 years
|
|
For participants with ET or PV: Duration of clinicohematologic response
Lasso di tempo: Up to ~10 years
|
For participants who showed clinicohematologic response in their feeder study, duration of clinicohematologic response is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC count until confirmed increase of platelet and WBC counts to above acceptable threshold, thrombotic or major hemorrhagic events or disease progression to MF, MDS, or AML, or phlebotomy (PV participants only). The duration of clinicohematologic response will be reported. |
Up to ~10 years
|
|
For participants with ET or PV: Duration of hematologic response
Lasso di tempo: Up to ~10 years
|
For participants who showed confirmed hematologic response in their feeder study, duration of hematologic response is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC count until confirmed increase of platelet and WBC counts to above acceptable threshold, or phlebotomy (PV participants only). The duration of hematologic response will be reported. |
Up to ~10 years
|
|
For participants with ET or PV: Percentage of participants with transformation to MF or MDS/AML
Lasso di tempo: Up to ~10 years
|
Disease Progression is defined as the transformation to post-ET myelofibrosis (ET participants only), post-PV myelofibrosis (PV participants only), spleen volume increase ≥25% (MF participants only), myelodysplastic syndrome, or acute myeloid leukemia as assessed by the investigator. The percentage of participants with transformation to MF or MDS/AML will be reported. |
Up to ~10 years
|
|
For participants with MF: Percentage of participants with worsening of splenomegaly or transformation to MDS/AML
Lasso di tempo: Up to ~10 years
|
Spleen volume will be assessed by magnetic resonance imaging (MRI) (or computed tomography [CT] where applicable) at pre-specified timepoints. The percentage of participants with worsening of splenomegaly or transformation to MDS/AML will be reported. |
Up to ~10 years
|
|
For participants with MF, ET, or PV: Percentage of participants with thrombotic events
Lasso di tempo: Up to ~10 years
|
Thrombotic events are defined as: new or recurrent acute myocardial infarction; unstable angina; stroke; transient ischemic attack (TIA); deep venous thrombosis (DVT); pulmonary embolism (PE); thrombotic digital ischemia; other thrombotic events such as peripheral limb ischemia or Budd-Chiari syndrome that are assessed to be due to underlying PV; other vascular occlusive events such as symptoms of cardiac, abdominal or peripheral limb ischemia supported by objective evidence of vessel disease and/or ischemia. The percentage of participants with thrombotic events will be presented. |
Up to ~10 years
|
|
For participants with MF, ET, or PV: Percentage of participants with major hemorrhagic events
Lasso di tempo: Up to ~10 years
|
Hemorrhagic events are defined as: Major Bleeding (MB) Events such as fatal bleeding, and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells; Clinically Relevant Non-Major Bleeding (CRNMB) Events Leading to hospitalization or increased level of care or clinically important, prompting a face-to-face medical evaluation. The percentage of participants with major hemorrhagic events will be presented. |
Up to ~10 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Medical Director, Merck Sharp and Dohme LLC
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie ematologiche
- Disturbi della coagulazione del sangue
- Malattie del midollo osseo
- Disturbi emorragici
- Disturbi delle piastrine del sangue
- Malattie mieloproliferative
- Neoplasie del midollo osseo
- Neoplasie ematologiche
- Malattie emiche e linfatiche
- Trombocitosi
- Trombocitemia, essenziale
- Policitemia vera
- Mielofibrosi primaria
- Bomedemstat
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 3543-017
- U1111-1294-8621 (Identificatore di registro: UTN)
- MK-3543-017 (Altro identificatore: MSD)
- 2023-506996-89-00 (Identificatore di registro: EU CT)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .